Welcome to our dedicated page for Haleon news (Ticker: HLN), a resource for investors and traders seeking the latest updates and insights on Haleon stock.
Haleon plc (HLN) generates a steady stream of news as a global consumer health company with a portfolio that spans Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. This news page aggregates coverage of Haleon’s brand activity, partnerships, research collaborations and corporate announcements, giving readers a single place to review the latest developments affecting the company and its well-known brands such as Advil, Centrum, Sensodyne, Voltaren and TUMS.
Recent news releases highlight how Haleon activates its brands through consumer campaigns and partnerships. TUMS has featured in promotions tied to major football events, including sweepstakes and themed games with partners like DraftKings and creator Eric Decker (Airrack), emphasising fast-acting relief from occasional heartburn during food-focused occasions. Other updates showcase product and packaging initiatives, such as the use of bio-based materials in the nasal spray pump used with Haleon’s Otrivin brand through a collaboration with Aptar Pharma.
Haleon’s news flow also reflects its focus on science and research. Announcements include the groundbreaking of a Global Oral Health Innovation Centre in Weybridge to act as an R&D hub for oral health, participation as the central industry partner in a UK-wide doctoral training programme on oral health, and a collaboration with Brightseed to use the Forager AI platform for discovering plant-based small molecules with potential health benefits.
Corporate and strategic updates appear alongside brand stories, including changes to Haleon’s operating model, leadership appointments and digital initiatives such as adopting Salesforce Life Sciences Cloud for Customer Engagement. Investors and observers can use this page to follow how Haleon’s category strategy, research focus and brand activations are reflected in its public announcements over time.
Haleon plc (LSE: HLN, NYSE: HLN) announced the start of exchange offers for seven series of outstanding unregistered notes from GSK Consumer Healthcare Capital. The offers aim to exchange these unregistered notes for registered notes under the Securities Act, expected to be listed on the NYSE. The exchange period ends at 5:00 p.m. (Eastern time) on October 28, 2022, with settlement anticipated on November 2, 2022. A registration statement related to the exchange notes was filed with the SEC on the same date.
New results from the COSMOS-Mind study indicate that participants taking Centrum Silver exhibited significant improvements in cognitive function compared to those on placebo. This study, involving over 2,000 older adults, highlights the potential benefits of multivitamin supplementation in addressing cognitive decline, a major concern as aging populations grow. The findings suggest that Centrum Silver could enhance memory and executive function, stressing its importance for healthy aging. The detailed report is available in the Alzheimer & Dementia Journal.
Nicorette has launched SmokeLess Break Beats, a unique music therapy initiative aimed at supporting smokers in their cessation journey. Developed with Berklee Music and Health Institute, the program features eight original tracks designed to promote relaxation, focus, and confidence. Available for free on Spotify, these playlists serve as behavioral tools during typical smoke breaks. The initiative underscores the science behind music's ability to reduce cravings and enhance psychological well-being, increasing the effectiveness of Nicotine Replacement Therapy by up to 70%.
Haleon, a leading independent consumer health company, has officially launched following its demerger from GSK plc. Trading on the London Stock Exchange began on July 18, 2022, with NYSE trading set to follow on July 20, 2022. Haleon boasts a robust brand portfolio, including Advil, Sensodyne, and TUMS, targeting an annual organic revenue growth of 4-6%. The company aims to address everyday health challenges and empower 50 million people by 2025. Haleon emphasizes its commitment to scientific innovation and consumer-centric solutions, focusing on the growing self-care market.